Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
News May 17, 2014
The CEO of Analytik Jena AG, Klaus Berka, has been appointed to the Advisory Board of the Fraunhofer Institute for Cell Therapy and Immunology (IZI).
Fraunhofer IZI, which was founded in Leipzig in 2005, researches and develops solutions to specific problems at the interfaces between medicine, life sciences, and engineering, such as drugs, cell therapy, diagnostics, and biobanks.
"I am pleased that I will have the opportunity as a member of this select board to help see to it that the institute can successfully and effectively continue its work in important pharmaceutical and therapeutic areas. I hope that I will be able to substantively enrich the work of the Advisory Board with my experience," Klaus Berka said. "Communication between science and business has been a very important personal concern of mine for many years."
In its Life Science business unit, Analytik Jena develops instruments, kits, and reagents in the area of biotechnology and molecular diagnostics that address a rapidly growing global market.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE
Bubble formation is typically a much more random process than liquid droplet formation, yet the generation of uniform drops and bubbles is very desirable in microfluidics. Researchers have now shown that under certain conditions, bubbles can also be coaxed to form spheres as perfectly matched as droplets.READ MORE